CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 64 enrolled
Drug / intervention
Octreotide LAR +3 moredrug
Likely dose
Octreotide LAR 30 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00332696
NCT00332696Phase 2Completed
CompareCT.gov

Evaluation of the Effect of Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Novartis Pharmaceuticals·interventional·Posted Jun 2, 2006·Updated Sep 23, 2011

In Brief

A Phase 2 clinical trial evaluating Octreotide LAR, Octreotide (Immediate release), and 2 other interventions for Peritoneal Neoplasms and 2 related conditions. Completed, enrolled 64 participants across 1 site.

Detailed Summary

To evaluate in combination with corticosteroid and local standard medical care the efficacy and safety of long-acting octreotide compared to placebo for the treatment of symptoms of inoperable bowel obstruction in patients with peritoneal carcinomatosis

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis
CountriesFrance
Collaborators--

Timeline

Phase 2CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJun 2, 2006
Enrollment StartSep 1, 2005
Primary CompletionSep 1, 2008
TodayJul 2, 2026
Enrollment to primary: 3 yearsPosted 20.1 years ago

Interventions

Octreotide LARdrug

Octreotide long-acting release (LAR) 30 mg intramuscular injection.

Octreotide (Immediate release)drug

Immediate-release Octreotide supplied in 100 µg/mL ampules.

methylprednisolonedrug

methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).

Placebodrug

Physiologic saline solution